WSI shares are surging in early trading on the 27th. The news that WSI's subsidiary has completed the core technology development for an oral obesity treatment is believed to have attracted investor sentiment.
As of 9:19 a.m. on that day, WSI shares are trading at 1,854 won, up 22.38% (339 won) from the previous trading day in the KOSDAQ market.
Before the opening that day, WSI's subsidiary IntroBioPharma announced that it had completed the core technology development for glucagon-like peptide-1 (GLP-1) analog oral obesity treatment and is currently conducting preclinical trials.
The company is reported to have confirmed the possibility of increasing the gastrointestinal absorption rate of polymer peptides by utilizing its self-developed EmulPass technology.
IntroBioPharma has established blood analysis methods necessary for obesity treatment development through its clinical trial subcontracting (CRO) subsidiary IVP Lab and is currently in the final stages of animal testing. The company plans to complete animal testing as early as the third quarter, secure a technology base through patent applications, and then start clinical trials.